ARTICLE | Clinical News
Apabetalone: Phase III started
November 2, 2015 8:00 AM UTC
Resverlogix began the double-blind, placebo-controlled, international Phase III BETonMACE trial to evaluate twice-daily 100 mg RVX-208 for up to 104 weeks in about 2,400 patients on high-dose statin t...